
I’m happy to share that our YELLOW-III study has been published in JACC: Cardiovascular Imaging. 110 stable coronary artery disease patients receiving maximally tolerated statin therapy were treated with evolocumab 140mg every 2 weeks for 26 weeks.
authors.elsevier.com/a/1mhDY,i2Xs4E…

English






































